Last reviewed · How we verify
Zoledronic acide (Aclasta)
At a glance
| Generic name | Zoledronic acide (Aclasta) |
|---|---|
| Sponsor | Prince of Wales Hospital, Shatin, Hong Kong |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients (PHASE3)
- Zoledronic Acid Compared to Percutaneous Treatment in Osteoid Osteoma (PHASE3)
- ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zoledronic acide (Aclasta) CI brief — competitive landscape report
- Zoledronic acide (Aclasta) updates RSS · CI watch RSS
- Prince of Wales Hospital, Shatin, Hong Kong portfolio CI